Former President Joe Biden announced this weekend that he has been diagnosed with an aggressive form of prostate cancer, the second leading cause of cancer death for men in the United States. About 1 ...

The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

A new urology lab with advanced diagnostic testing is up and running at UPMC St. Margaret Hospital to deal with a slow but steady increase in the number of prostate cancer cases diagnosed each year.

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending drug abiraterone, in clinical trial results presented by scientists from ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Investigators sought to determine the effect of “Smart PSA” guidelines on screening behavior and biopsy outcomes among Black men.

Former President Joe Biden and other older men may not be getting routine prostate cancer screenings but his recent Stage 4 diagnosis raises questions about whether that's always the best choice.

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...

Maurice Blake says he never knew that one-in-four black men face prostate cancer - double the average.